regardless of promising clinical data, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing considerable resistance from PBMs. These companies are frequently building obstacles to reimbursement, including steep expense requirements and prior authorization that hinder user opportunity. Analy… Read More